NCT02418598View on ClinicalTrials.gov

AADC Gene Therapy for Parkinson's Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Parkinson Disease
Interventions
GENETIC

Cohort1

AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.

GENETIC

Cohort2

AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.

Trial Locations (1)

3290498

Jichi Medical University, Shimotsuke

Sponsors
All Listed Sponsors
collaborator

Takara Bio Inc.

INDUSTRY

collaborator

Gene Therapy Research Institution,Co.,Ltd.

UNKNOWN

lead

Jichi Medical University

OTHER